Sequence: HAIYPRH
| Experiment Id | EXP002456 |
|---|---|
| Paper | Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated |
| Peptide | T7 peptide-decorated exosome |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | not reported as peptide concentration; T7 is displayed on exosome surface via T7-Lamp2b expression |
| Rna Concentration | In vitro: FAM-AMO-21 amount fixed at 1 ug/well for uptake assay; loading used 20 ug AMO-21 with 20 ug exosome protein. In vivo: 60 ug AMO-21 electroporated with exosomes per rat before purification; 200 ug exosomes used for fluorescence imaging. |
| Mixing Ratio | AMO-21 loaded into exosomes by electroporation; 20 ug exosome protein mixed with 20 ug AMO-21 in 400 uL PBS for loading assay. |
| Formulation Format | T7 peptide-decorated exosome loaded with AMO-21 by electroporation |
| Formulation Components | T7-Lamp2b-displaying exosomes, AMO-21 anti-miR oligonucleotide |
| Size Nm | 15.00 |
| Zeta Mv | -10.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | C6 cells used for orthotopic tumor implantation |
| Animal Model | Intracranial C6 glioblastoma Sprague Dawley rat model |
| Administration Route | intravenous tail-vein injection |
| Output Type | brain delivery; miR-21 knockdown; PDCD4/PTEN restoration; tumor suppression |
| Output Value | T7-exo delivered AMO-21 to brain more efficiently than unmodified and RVG exosomes; tumor miR-21 decreased to ~20% of control; PDCD4 and PTEN increased; T7-exo/AMO-21 reduced relative tumor size to roughly one-third of control and outperformed scrAMO-21 control. |
| Output Units | |
| Output Notes | In vivo delivery success is positive because systemic T7-exo/AMO-21 produced functional anti-miR activity and reduced orthotopic glioblastoma tumor size. |
| Toxicity Notes | No systemic toxicity study reported; exosome biocompatibility supported by in vitro viability and rat RBC hemocompatibility assays. |
| Curation Notes |